Jazz Pharmaceuticals - JAZZ Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $195.90
  • Forecasted Upside: 51.04%
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$129.70
▼ -2.56 (-1.94%)

This chart shows the closing price for JAZZ by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Jazz Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for JAZZ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for JAZZ

Analyst Price Target is $195.90
▲ +51.04% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Jazz Pharmaceuticals in the last 3 months. The average price target is $195.90, with a high forecast of $235.00 and a low forecast of $135.00. The average price target represents a 51.04% upside from the last price of $129.70.

This chart shows the closing price for JAZZ for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 11 contributing investment analysts is to moderate buy stock in Jazz Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/6/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/5/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/5/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/3/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/1/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/30/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/29/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/29/2024BarclaysLower TargetOverweight ➝ Overweight$240.00 ➝ $235.00Low
1/3/2024Robert W. BairdInitiated CoverageOutperform$160.00Low
12/4/2023Truist FinancialReiterated RatingBuy ➝ Buy$200.00Low
11/29/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$225.00Low
11/27/2023UBS GroupDowngradeBuy ➝ Neutral$170.00 ➝ $135.00Low
11/9/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$200.00 ➝ $191.00Low
11/9/2023Needham & Company LLCLower TargetBuy ➝ Buy$226.00 ➝ $225.00Low
9/28/2023Raymond JamesInitiated CoverageMarket PerformLow
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$180.00Low
8/14/2023Cantor FitzgeraldLower TargetOverweight ➝ Overweight$210.00 ➝ $180.00Low
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$204.00Low
8/10/2023Bank of AmericaBoost TargetBuy ➝ Buy$204.00 ➝ $217.00Low
8/10/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$203.00 ➝ $201.00Low
8/7/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$226.00Low
7/10/2023Cantor FitzgeraldReiterated RatingOverweightLow
5/11/2023Royal Bank of CanadaLower Target$207.00 ➝ $202.00Low
5/11/2023Needham & Company LLCBoost Target$205.00 ➝ $212.00Low
3/6/2023HC WainwrightReiterated RatingBuy$204.00Low
3/3/2023The Goldman Sachs GroupBoost TargetBuy$190.00 ➝ $212.00Low
3/2/2023Needham & Company LLCLower TargetBuy$210.00 ➝ $205.00Low
12/8/2022The Goldman Sachs GroupUpgradeNeutral ➝ Buy$192.00 ➝ $190.00Low
11/10/2022The Goldman Sachs GroupBoost TargetNeutral$170.00 ➝ $192.00Low
11/10/2022Royal Bank of CanadaBoost TargetOutperform$206.00 ➝ $207.00Low
11/10/2022Needham & Company LLCLower TargetBuy$210.00 ➝ $208.00Low
9/29/2022The Goldman Sachs GroupBoost TargetNeutral$148.00 ➝ $170.00Low
9/21/2022The Goldman Sachs GroupLower TargetNeutral$192.00 ➝ $148.00Low
8/5/2022HC WainwrightLower Target$210.00 ➝ $204.00Low
8/4/2022BMO Capital MarketsBoost TargetOutperform$185.00 ➝ $188.00Low
8/4/2022SVB LeerinkBoost TargetOutperform$200.00 ➝ $210.00Low
8/4/2022UBS GroupLower TargetBuy$194.00 ➝ $191.00Low
8/4/2022Morgan StanleyBoost TargetEqual Weight$174.00 ➝ $187.00N/A
6/13/2022UBS GroupInitiated CoverageBuy$194.00Medium
5/5/2022CowenBoost Target$200.00 ➝ $225.00Low
5/5/2022CowenBoost Target$200.00 ➝ $225.00Low
5/5/2022Piper SandlerLower Target$197.00 ➝ $193.00Low
4/6/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral$202.00 ➝ $196.00High
3/3/2022HC WainwrightBoost TargetBuy$210.00 ➝ $215.00Low
3/2/2022Cantor FitzgeraldReiterated RatingOverweightLow
3/2/2022Piper SandlerLower TargetOverweight$209.00 ➝ $197.00High
3/2/2022Royal Bank of CanadaLower TargetOutperform$216.00 ➝ $214.00High
3/2/2022BMO Capital MarketsLower Target$202.00 ➝ $187.00High
2/7/2022Needham & Company LLCReiterated RatingBuy$215.00Low
1/20/2022Truist FinancialBoost Target$180.00 ➝ $200.00Low
12/20/2021SVB LeerinkLower TargetOutperform$230.00 ➝ $200.00Low
12/17/2021Needham & Company LLCLower TargetBuy$220.00 ➝ $215.00Medium
11/18/2021The Goldman Sachs GroupInitiated CoverageBuyHigh
10/8/2021Morgan StanleyLower TargetEqual Weight$176.00 ➝ $174.00Low
10/5/2021CitigroupInitiated CoverageBuy$200.00Medium
9/22/2021Needham & Company LLCInitiated CoverageBuy$220.00High
8/16/2021HC WainwrightLower TargetBuy$220.00 ➝ $210.00Low
7/23/2021Royal Bank of CanadaBoost TargetOutperform$190.00 ➝ $216.00Low
7/22/2021SVB LeerinkReiterated RatingBuyLow
7/6/2021Jefferies Financial GroupInitiated CoverageBuy$220.00Low
6/22/2021BarclaysBoost TargetOverweight$235.00 ➝ $250.00Low
6/21/2021HC WainwrightBoost TargetBuy$212.00 ➝ $220.00Low
6/18/2021SVB LeerinkBoost TargetOutperform$210.00 ➝ $230.00Low
5/24/2021Piper SandlerReiterated RatingBuy$214.00Low
5/19/2021JPMorgan Chase & Co.Initiated CoverageOverweightLow
5/17/2021HC WainwrightBoost TargetBuy$207.00 ➝ $212.00Medium
5/9/2021SVB LeerinkReiterated RatingBuyLow
5/7/2021Jefferies Financial GroupReiterated RatingBuyLow
4/21/2021Cantor FitzgeraldBoost TargetOverweight$185.00 ➝ $198.00Medium
4/14/2021Stifel NicolausBoost TargetBuy$195.00 ➝ $202.00High
4/1/2021Morgan StanleyBoost TargetEqual Weight$162.00 ➝ $176.00Low
3/15/2021SVB LeerinkReiterated RatingOutperformMedium
3/1/2021UBS GroupBoost TargetBuy$174.00 ➝ $228.00Low
2/25/2021SVB LeerinkLower TargetOutperform$213.00 ➝ $210.00Medium
2/24/2021CowenBoost TargetOutperform$190.00 ➝ $200.00High
2/24/2021Jefferies Financial GroupBoost TargetBuy$209.00 ➝ $214.00High
2/24/2021Piper SandlerBoost TargetOverweight$175.00 ➝ $205.00High
2/5/2021HC WainwrightBoost TargetBuy$195.00 ➝ $207.00High
2/3/2021Piper SandlerUpgradeNeutral ➝ Overweight$150.00 ➝ $175.00High
1/29/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$177.00 ➝ $162.00High
12/15/2020UBS GroupInitiated CoverageBuy$174.00High
11/3/2020Wells Fargo & CompanyBoost TargetOverweight$171.00 ➝ $184.00High
11/3/2020Royal Bank of CanadaBoost TargetOutperform$170.00 ➝ $180.00High
11/3/2020BarclaysBoost TargetOverweight$225.00 ➝ $233.00High
11/3/2020SVB LeerinkBoost TargetOutperform$194.00 ➝ $202.00High
11/3/2020HC WainwrightBoost TargetBuy$185.00 ➝ $195.00High
10/26/2020BarclaysBoost TargetOverweight$205.00 ➝ $225.00Low
10/20/2020Truist FinancialBoost Target$157.00 ➝ $175.00Medium
10/9/2020Jefferies Financial GroupBoost TargetBuy$151.00 ➝ $188.00Low
10/9/2020SVB LeerinkBoost TargetOutperform$164.00 ➝ $182.00Low
10/9/2020HC WainwrightBoost TargetBuy$175.00 ➝ $185.00Low
9/14/2020Royal Bank of CanadaBoost Target$160.00 ➝ $170.00Low
9/14/2020JPMorgan Chase & Co.Initiated CoverageOverweight$175.00Medium
9/14/2020The Goldman Sachs GroupDowngradeNeutral ➝ Sell$128.00Medium
8/13/2020Wells Fargo & CompanyBoost TargetOverweight$150.00 ➝ $171.00Low
8/6/2020BarclaysReiterated RatingBuyHigh
8/6/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$177.00High
7/30/2020OppenheimerInitiated CoverageOutperformHigh
7/28/2020Wolfe ResearchUpgradePeer Perform ➝ OutperformLow
7/23/2020HC WainwrightUpgradeNeutral ➝ Buy$145.00 ➝ $166.00Medium
6/23/2020BarclaysBoost TargetOverweight$183.00 ➝ $195.00Low
6/18/2020Bank of AmericaBoost TargetBuy$165.00 ➝ $167.00Low
6/1/2020SVB LeerinkBoost TargetOutperform$160.00 ➝ $169.00Low
5/6/2020SunTrust BanksLower TargetBuy$155.00 ➝ $153.00Medium
5/6/2020OppenheimerReiterated RatingBuy$132.00Medium
5/6/2020SVB LeerinkLower TargetOutperform$169.00 ➝ $160.00Medium
5/6/2020BMO Capital MarketsLower TargetPositive ➝ Outperform$205.00 ➝ $193.00High
5/6/2020Piper SandlerLower TargetNeutral$127.00 ➝ $113.00High
4/30/2020Wells Fargo & CompanyLower TargetOverweight$189.00 ➝ $162.00Low
4/30/2020OppenheimerLower TargetOutperform$154.00 ➝ $141.00Low
4/6/2020Jefferies Financial GroupInitiated CoverageBuy$149.00High
4/2/2020Morgan StanleyLower TargetEqual Weight$147.00 ➝ $109.00Medium
3/30/2020Royal Bank of CanadaLower Target$164.00 ➝ $174.00Medium
3/23/2020Bank of AmericaLower TargetBuy$178.00 ➝ $163.00High
3/12/2020Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$175.00 ➝ $166.00High
2/27/2020SunTrust BanksLower TargetBuy$171.00 ➝ $166.00High
2/26/2020OppenheimerLower Target$183.00 ➝ $154.00High
2/26/2020Piper SandlerLower Target$142.00 ➝ $129.00High
2/26/2020BMO Capital MarketsLower TargetOutperform$208.00 ➝ $205.00High
2/26/2020Royal Bank of CanadaReiterated RatingOutperform$164.00High
2/26/2020CowenLower TargetOutperform$200.00 ➝ $165.00High
2/26/2020JPMorgan Chase & Co.Boost TargetOverweight$173.00 ➝ $183.00High
1/31/2020SunTrust BanksReiterated RatingBuy$166.00 ➝ $171.00Low
1/22/2020Wells Fargo & CompanyBoost TargetOverweight$186.00 ➝ $189.00Low
1/8/2020The Goldman Sachs GroupInitiated CoverageNeutral$153.00Medium
12/3/2019Wells Fargo & CompanyBoost TargetOutperform$168.00 ➝ $186.00High
12/2/2019BarclaysBoost TargetOverweight$182.00 ➝ $200.00Low
11/11/2019HC WainwrightReiterated RatingHold$147.00Medium
11/11/2019Evercore ISIReiterated RatingBuyMedium
11/7/2019BarclaysReiterated RatingBuy$182.00Medium
10/14/2019Sanford C. BernsteinReiterated RatingMarket Perform$150.00Low
9/26/2019OppenheimerSet TargetBuy$176.00Low
8/21/2019Piper Sandler CompaniesDowngradeOverweight ➝ Neutral$205.00 ➝ $142.00High
8/14/2019Wells Fargo & CompanyReiterated RatingBuyLow
8/12/2019Evercore ISIReiterated RatingBuyMedium
8/8/2019HC WainwrightReiterated RatingHold$147.00Low
8/7/2019BarclaysBoost TargetOverweight$164.00 ➝ $180.00High
7/8/2019OppenheimerSet TargetBuy$176.00Low
7/3/2019Royal Bank of CanadaSet TargetBuy$184.00Low
7/3/2019BarclaysSet TargetBuy$164.00Low
7/3/2019BMO Capital MarketsSet TargetBuy$208.00Low
7/3/2019MizuhoSet TargetHold$148.00Low
6/17/2019Wells Fargo & CompanyReiterated RatingBuyLow
6/11/2019BarclaysInitiated CoverageOverweight ➝ Overweight$164.00Low
5/28/2019Piper Sandler CompaniesSet TargetBuy$202.00Low
5/10/2019HC WainwrightReiterated RatingHold$153.00Low
5/8/2019MizuhoBoost TargetNeutral$146.00 ➝ $148.00High
5/8/2019BMO Capital MarketsBoost TargetOutperform$206.00 ➝ $208.00High
3/27/2019MizuhoReiterated RatingNeutral ➝ Hold$137.00 ➝ $147.00Medium
3/26/2019Cantor FitzgeraldReiterated RatingBuy$185.00Medium
3/19/2019SunTrust BanksInitiated CoverageBuy ➝ Buy$163.00Medium
3/19/2019Wells Fargo & CompanySet TargetBuy$162.00Low
3/18/2019Royal Bank of CanadaSet TargetBuy$184.00Low
3/8/2019Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$168.00 ➝ $135.00Medium
(Data available from 2/28/2019 forward)

News Sentiment Rating

0.82 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 19 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
8/2/2023
  • 14 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/1/2023
  • 17 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/1/2023
  • 7 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
10/31/2023
  • 5 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
11/30/2023
  • 8 very positive mentions
  • 10 positive mentions
  • 6 negative mentions
  • 4 very negative mentions
12/30/2023
  • 9 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/29/2024
  • 27 very positive mentions
  • 24 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
2/28/2024

Current Sentiment

  • 27 very positive mentions
  • 24 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Jazz Pharmaceuticals logo
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy and idiopathic hypersomnia (IH); Xyrem, a sodium oxybate oral solution for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older; and Epidiolex, a cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. The company's lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer; Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. coli-derived asparaginase; Vyxeos, a liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. It has licensing and collaboration agreements with Zymeworks Inc.; Sumitomo Pharma Co., Ltd; Werewolf Therapeutics, Inc.; Codiak BioSciences, Inc.; Ligand Pharmaceuticals Incorporated; XL-protein GmbH; and Redx Pharma plc. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $129.70
Low: $129.18
High: $132.85

50 Day Range

MA: $123.62
Low: $115.19
High: $132.77

52 Week Range

Now: $129.70
Low: $111.25
High: $147.98

Volume

697,834 shs

Average Volume

526,460 shs

Market Capitalization

$8.17 billion

P/E Ratio

147.39

Dividend Yield

N/A

Beta

0.62

Frequently Asked Questions

What sell-side analysts currently cover shares of Jazz Pharmaceuticals?

The following Wall Street research analysts have issued stock ratings on Jazz Pharmaceuticals in the last twelve months: Bank of America Co., Barclays PLC, Cantor Fitzgerald, HC Wainwright, Needham & Company LLC, Raymond James, Robert W. Baird, Royal Bank of Canada, StockNews.com, The Goldman Sachs Group, Inc., Truist Financial Co., and UBS Group AG.
View the latest analyst ratings for JAZZ.

What is the current price target for Jazz Pharmaceuticals?

10 Wall Street analysts have set twelve-month price targets for Jazz Pharmaceuticals in the last year. Their average twelve-month price target is $195.90, suggesting a possible upside of 51.0%. Barclays PLC has the highest price target set, predicting JAZZ will reach $235.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $135.00 for Jazz Pharmaceuticals in the next year.
View the latest price targets for JAZZ.

What is the current consensus analyst rating for Jazz Pharmaceuticals?

Jazz Pharmaceuticals currently has 2 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for JAZZ.

What other companies compete with Jazz Pharmaceuticals?

How do I contact Jazz Pharmaceuticals' investor relations team?

Jazz Pharmaceuticals' physical mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company's listed phone number is (531) 634-7800 and its investor relations email address is [email protected]. The official website for Jazz Pharmaceuticals is www.jazzpharma.com. Learn More about contacing Jazz Pharmaceuticals investor relations.